Literature DB >> 26162714

UNC13A confers risk for sporadic ALS and influences survival in a Spanish cohort.

Jose Manuel Vidal-Taboada1,2, Alan Lopez-Lopez3,4, Maria Salvado5, Laura Lorenzo5, Cecilia Garcia5, Nicole Mahy3,4, Manuel J Rodríguez3,4, Josep Gamez6.   

Abstract

To investigate the association of functional variants of the human UNC13A gene with the risk of ALS, survival and the disease progression rate in a Spanish ALS cohort. 136 sporadic ALS (sALS) patients and 487 healthy controls were genotyped for the UNC13A rs12608932 variant. Clinical characterization of ALS patients included gender, age at first symptom, initial topography, disease progression rate, and survival. Genetic association was analyzed under five inheritance models. The sALS patients with the rs12608932(CC) genotype had an increased risk of ALS under a recessive genetic model [OR 2.16; 95 % CI (1.23, 3.8), p = 0.009; corrected p = 0.028]. Genotypes with a C allele are also associated with increased risk [OR 1.47; 95 % CI (1.11, 1.95); p = 0.008; corrected p = 0.023] under an additive model. sALS patients with a C/C genotype had a shorter survival than patients with A/A and A/C genotypes [HR 1.44; 95 % CI (1.11, 1.873); p = 0.007] under a recessive model. In an overdominant model, heterozygous patients had a longer survival than homozygous patients [HR 0.36; 95 % CI (0.22, 0.59); p = 0.001]. The rs12608932 genotypes modify the progression of symptoms measured using the ALSFRS-R. No association with age of onset, initial topography or rate of decline in FVC was found. Our results show that rs12608932 is a risk factor for ALS in the Spanish population and replicate the findings described in other populations. The rs12608932 is a modifying factor for survival and disease progression rate in our series. Our results also corroborated that it did not influence the age of onset.

Entities:  

Keywords:  ALS; Amyotrophic lateral sclerosis; Modifying gene; Susceptibility; UNC13A; rs12608932

Mesh:

Substances:

Year:  2015        PMID: 26162714     DOI: 10.1007/s00415-015-7843-z

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  45 in total

1.  Are the El Escorial and Revised El Escorial criteria for ALS reproducible? A study of inter-observer agreement.

Authors:  R B Forbes; S Colville; R J Swingler
Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord       Date:  2001-09

2.  ALS: disease or syndrome?

Authors:  Leonard H van den Berg
Journal:  J Neurol Neurosurg Psychiatry       Date:  2011-04-02       Impact factor: 10.154

Review 3.  Prognostic factors for the course of functional status of patients with ALS: a systematic review.

Authors:  Huub Creemers; Hepke Grupstra; Frans Nollet; Leonard H van den Berg; Anita Beelen
Journal:  J Neurol       Date:  2014-11-11       Impact factor: 4.849

4.  Transcriptional response of human microglial cells to interferon-gamma.

Authors:  R B Rock; S Hu; A Deshpande; S Munir; B J May; C A Baker; P K Peterson; V Kapur
Journal:  Genes Immun       Date:  2005-12       Impact factor: 2.676

5.  Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: a genome-wide association study.

Authors:  Hannu Laaksovirta; Terhi Peuralinna; Jennifer C Schymick; Sonja W Scholz; Shaoi-Lin Lai; Liisa Myllykangas; Raimo Sulkava; Lilja Jansson; Dena G Hernandez; J Raphael Gibbs; Michael A Nalls; David Heckerman; Pentti J Tienari; Bryan J Traynor
Journal:  Lancet Neurol       Date:  2010-10       Impact factor: 44.182

6.  Aberrant morphology and residual transmitter release at the Munc13-deficient mouse neuromuscular synapse.

Authors:  Frédérique Varoqueaux; Michèle S Sons; Jaap J Plomp; Nils Brose
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

7.  Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

Authors:  Paul H Gordon; Dan H Moore; Robert G Miller; Julaine M Florence; Joseph L Verheijde; Carolyn Doorish; Joan F Hilton; G Mark Spitalny; Robert B MacArthur; Hiroshi Mitsumoto; Hans E Neville; Kevin Boylan; Tahseen Mozaffar; Jerry M Belsh; John Ravits; Richard S Bedlack; Michael C Graves; Leo F McCluskey; Richard J Barohn; Rup Tandan
Journal:  Lancet Neurol       Date:  2007-11-05       Impact factor: 44.182

8.  Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study.

Authors:  Aleksey Shatunov; Kin Mok; Stephen Newhouse; Michael E Weale; Bradley Smith; Caroline Vance; Lauren Johnson; Jan H Veldink; Michael A van Es; Leonard H van den Berg; Wim Robberecht; Philip Van Damme; Orla Hardiman; Anne E Farmer; Cathryn M Lewis; Amy W Butler; Olubunmi Abel; Peter M Andersen; Isabella Fogh; Vincenzo Silani; Adriano Chiò; Bryan J Traynor; Judith Melki; Vincent Meininger; John E Landers; Peter McGuffin; Jonathan D Glass; Hardev Pall; P Nigel Leigh; John Hardy; Robert H Brown; John F Powell; Richard W Orrell; Karen E Morrison; Pamela J Shaw; Christopher E Shaw; Ammar Al-Chalabi
Journal:  Lancet Neurol       Date:  2010-10       Impact factor: 44.182

9.  Astroglia-Microglia Cross Talk during Neurodegeneration in the Rat Hippocampus.

Authors:  Montserrat Batlle; Lorenzo Ferri; Carmen Andrade; Francisco-Javier Ortega; Jose M Vidal-Taboada; Marco Pugliese; Nicole Mahy; Manuel J Rodríguez
Journal:  Biomed Res Int       Date:  2015-04-21       Impact factor: 3.411

Review 10.  Risk factors for amyotrophic lateral sclerosis.

Authors:  Caroline Ingre; Per M Roos; Fredrik Piehl; Freya Kamel; Fang Fang
Journal:  Clin Epidemiol       Date:  2015-02-12       Impact factor: 4.790

View more
  14 in total

1.  Common polymorphisms of chemokine (C-X3-C motif) receptor 1 gene modify amyotrophic lateral sclerosis outcome: A population-based study.

Authors:  Andrea Calvo; Cristina Moglia; Antonio Canosa; Stefania Cammarosano; Antonio Ilardi; Davide Bertuzzo; Bryan J Traynor; Maura Brunetti; Marco Barberis; Gabriele Mora; Federico Casale; Adriano Chiò
Journal:  Muscle Nerve       Date:  2017-04-25       Impact factor: 3.217

2.  Association of the CX3CR1-V249I Variant with Neurofibrillary Pathology Progression in Late-Onset Alzheimer's Disease.

Authors:  Alan López-López; Ellen Gelpi; Diana Maria Lopategui; Jose M Vidal-Taboada
Journal:  Mol Neurobiol       Date:  2017-03-25       Impact factor: 5.590

3.  UNC13A variant rs12608932 is associated with increased risk of amyotrophic lateral sclerosis and reduced patient survival: a meta-analysis.

Authors:  Baiyuan Yang; Haixia Jiang; Fang Wang; Shimei Li; Chongmin Wu; Jianjian Bao; Yongyun Zhu; Zhong Xu; Bin Liu; Hui Ren; Xinglong Yang
Journal:  Neurol Sci       Date:  2019-06-14       Impact factor: 3.307

4.  KATP Channel Expression and Genetic Polymorphisms Associated with Progression and Survival in Amyotrophic Lateral Sclerosis.

Authors:  José M Vidal-Taboada; Marco Pugliese; Maria Salvadó; Josep Gámez; Nicole Mahy; Manuel J Rodríguez
Journal:  Mol Neurobiol       Date:  2018-02-28       Impact factor: 5.590

Review 5.  Amyotrophic Lateral Sclerosis: Current Status in Diagnostic Biomarkers.

Authors:  Katerina Kadena; Panayiotis Vlamos
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

6.  UNC13A polymorphism contributes to frontotemporal disease in sporadic amyotrophic lateral sclerosis.

Authors:  Katerina Placek; G Michael Baer; Lauren Elman; Leo McCluskey; Laura Hennessy; Pilar M Ferraro; Edward B Lee; Virginia M Y Lee; John Q Trojanowski; Vivianna M Van Deerlin; Murray Grossman; David J Irwin; Corey T McMillan
Journal:  Neurobiol Aging       Date:  2018-09-27       Impact factor: 4.673

7.  Rare genetic variation in UNC13A may modify survival in amyotrophic lateral sclerosis.

Authors:  Benjamin Gaastra; Aleksey Shatunov; Sara Pulit; Ashley R Jones; William Sproviero; Alexandra Gillett; Zhongbo Chen; Janine Kirby; Isabella Fogh; John F Powell; P Nigel Leigh; Karen E Morrison; Pamela J Shaw; Christopher E Shaw; Leonard H van den Berg; Jan H Veldink; Cathryn M Lewis; Ammar Al-Chalabi
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2016-09-01       Impact factor: 4.092

8.  Modulation of nuclear REST by alternative splicing: a potential therapeutic target for Huntington's disease.

Authors:  Guo-Lin Chen; Qi Ma; Dharmendra Goswami; Jianyu Shang; Gregory M Miller
Journal:  J Cell Mol Med       Date:  2017-05-19       Impact factor: 5.310

Review 9.  Recent advances in amyotrophic lateral sclerosis.

Authors:  Nilo Riva; Federica Agosta; Christian Lunetta; Massimo Filippi; Angelo Quattrini
Journal:  J Neurol       Date:  2016-03-30       Impact factor: 4.849

Review 10.  Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials.

Authors:  Ruben P A van Eijk; Ashley R Jones; William Sproviero; Aleksey Shatunov; Pamela J Shaw; P Nigel Leigh; Carolyn A Young; Christopher E Shaw; Gabriele Mora; Jessica Mandrioli; Giuseppe Borghero; Paolo Volanti; Frank P Diekstra; Wouter van Rheenen; Esther Verstraete; Marinus J C Eijkemans; Jan H Veldink; Adriano Chio; Ammar Al-Chalabi; Leonard H van den Berg; Michael A van Es
Journal:  Neurology       Date:  2017-10-04       Impact factor: 11.800

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.